Overview
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Eligibility
Inclusion Criteria
- Participant has documented diagnosis of multiple myeloma and measurable disease, defined as any of the following:. i) Myeloma-protein (M-protein) ≥ 0.5 grams/deciliter (g/dL) by serum protein electrophoresis (sPEP), or.
ii) M-protein ≥ 200 milligrams (mg)/24-hour urine collection by urine protein
electrophoresis (uPEP) or,.
iii) For participants without measurable disease in sPEP or uPEP: serum free light chain
levels > 100 mg/liter (L) (10 mg/dL) involved light chain and an abnormal κ/λ free light
chain ratio.
- Participant has received at least one prior line of anti-myeloma therapy. Note: One
line can contain several phases (e.g., induction, [with or without] hematopoietic stem
cell transplant, (with or without) consolidation, and/or [with or without] maintenance
therapy).
- Participant must have received prior treatment with lenalidomide and at least 2 cycles
of an anti-CD38 monoclonal antibody (mAb) (participants who were intolerant of an
anti-CD38 mAb and received < 2 cycles are still eligible).
- Participant achieved minimal response or better to at least 1 prior anti-myeloma
therapy.
- Participant must have documented disease progression during or after their last
antimyeloma regimen.
Exclusion Criteria
- Participant who has had prior treatment with mezigdomide or carfilzomib.
- Participant has previously received allogeneic stem cell transplant at any time or
received autologous stem cell transplant within 12 weeks of initiating study
treatment.
- Other protocol-defined Inclusion/Exclusion criteria apply.